Safinamide
| Title | Journal |
|---|---|
| 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases. | Bioorganic & medicinal chemistry 20131201 |
| A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. | mBio 20130101 |
| Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers. | Pharmacology 20130101 |
| The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. | Clinical pharmacology and therapeutics 20121001 |
| Emerging therapies for Parkinson's disease. | Current opinion in neurology 20120801 |
| Managing the patient with newly diagnosed Parkinson disease. | Cleveland Clinic journal of medicine 20120701 |
| A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. | Movement disorders : official journal of the Movement Disorder Society 20120101 |
| Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones. | Journal of medicinal chemistry 20111208 |
| Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers. | Naunyn-Schmiedeberg's archives of pharmacology 20111201 |
| Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. | CNS drugs 20111201 |
| Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies. | Current topics in medicinal chemistry 20111101 |
| 3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: a new scaffold for the selective inhibition of monoamine oxidase B. | Journal of medicinal chemistry 20110922 |
| Medical management of Parkinson's disease: focus on neuroprotection. | Current neuropharmacology 20110601 |
| A validated chiral liquid chromatographic method for the enantiomeric separation of safinamide mesilate, a new anti-Parkinson drug. | Journal of pharmaceutical and biomedical analysis 20110428 |
| Available and emerging treatments for Parkinson's disease: a review. | Drug design, development and therapy 20110101 |
| Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease). | Journal of drug delivery 20110101 |
| Safinamide in the treatment of Parkinson's disease. | Expert opinion on pharmacotherapy 20100901 |
| The Movement Disorder Society--14th International Congress of Parkinson's Disease and Movement Disorders. | IDrugs : the investigational drugs journal 20100801 |
| Two polymorphs of safinamide, a selective and reversible inhibitor of monoamine oxidase B. | Acta crystallographica. Section C, Crystal structure communications 20100601 |
| Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities. | Journal of medicinal chemistry 20100513 |
| Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. | Drugs of today (Barcelona, Spain : 1998) 20100401 |
| Superpose3D: a local structural comparison program that allows for user-defined structure representations. | PloS one 20100101 |
| Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. | Pharmacological reports : PR 20090101 |
| An expert opinion on safinamide in Parkinson's disease. | Expert opinion on investigational drugs 20080701 |
| Computational systems analysis of dopamine metabolism. | PloS one 20080101 |
| Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. | Pharmacotherapy 20071201 |
| Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. | Journal of medicinal chemistry 20071115 |
| Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. | Journal of medicinal chemistry 20071004 |
| Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. | Current opinion in investigational drugs (London, England : 2000) 20070701 |
| Safinamide. | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20070101 |
| Safinamide: from molecular targets to a new anti-Parkinson drug. | Neurology 20061010 |
| Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. | Neurology 20061010 |
| New pharmacologic horizons in the treatment of Parkinson disease. | Neurology 20061010 |
| Bioassay of safinamide in biological fluids of humans and various animal species. | Arzneimittel-Forschung 20060101 |
| Voltage gated ion channels: targets for anticonvulsant drugs. | Current topics in medicinal chemistry 20050101 |
| Improvement of motor function in early Parkinson disease by safinamide. | Neurology 20040824 |
| Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. | Pharmacological research 20040701 |
| Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. | Journal of medicinal chemistry 20040325 |
| Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E. | Drugs in R&D 20040101 |
| Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). | Epilepsy research 20040101 |
| Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. | Clinical neuropharmacology 20030101 |
| Novel anticonvulsant medications in development. | Expert opinion on investigational drugs 20021001 |
| Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). | Epilepsy research 20020901 |
| Safinamide (Newron Pharmaceuticals). | Current opinion in investigational drugs (London, England : 2000) 20010601 |
| Future prospects for the drug treatment of epilepsy. | CNS drugs 20010101 |